Steven I Park MD

Hematologic Oncology

Professor, Wake Forest University School of Medicine; Vice Chair for Research, Levine Cancer Institute, North Carolina

1021 Morehead Medical DriveCharlotte, NC 28204
Phone+1 704-403-0005

Dr. Park is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Park's full profile Already have an account?

Summary

Lymphoma expert specializing in Hodgkin lymphoma, Non-Hodgkin lymphoma, and Chronic lymphocytic leukemia.

Google Scholar - Steven I Park, MD

Clinical Expertise

Non-Hodgkin lymphoma, Hodgkin's lymphoma, Hematologic oncology, Lymphoma

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2009
University of WashingtonResidency, Internal Medicine, 2002 - 2005
University of California, Davis, School of MedicineClass of 2002
University of California, BerkeleyBA

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2009 - 2027
WA State Medical License 2005 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2013-2014, 2016-2017

Clinical Trials

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
COMPLETED
PHASE2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 28
COMPLETED
PHASE2
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
COMPLETED
NA

Publications & Presentations

PubMed

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Man...
Stephen D Smith, Suchitra Sundaram, Sharmila Giri, Andy Ness, Yucai Wang
American Journal of Hematology. 2026-09-01
2 citations
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax inrearranged lymphomas.
Rajeswaran Mani, Samon Benrashid, Margaret D Templeton, Lawrence J Druhan, Sara L Seegers
Iscience. 2025-06-20
2 citations
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.
Nilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, Danielle Boselli, Gray Magee
JCO Oncology Practice. 2025-05-01

Abstracts/Posters

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019